Dallah Healthcare Receives Competition Authority Approval for SAR 498M Sale

DALLAH HEALTH

DALLAH HEALTH

4004.SA

0.00

Dallah Healthcare Company announced on June 14, 2026 recent developments regarding its previously disclosed share sale transaction with Dr. Soliman Abdel Kader Fakeeh Hospital Co. The company received non-objection approval from the General Authority for Competition on June 11, 2026 for the economic concentration resulting from the sale of its entire 31.21% shareholding in Dr. Mohammed bin Rashid Al Fagih & Partners Company valued at SAR 497,983,407. The transaction remains subject to other conditions precedent, with the original sale agreement announced on May 6, 2026.

Original announcement:

https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=96057&anCat=1&cs=4004&locale=ar

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.